All Photos(1)

Documents

Y0000764

Fluorouracil impurity C

Name: Fluorouracil impurity C
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Uracil, 2,4(1H,3H)-Pyrimidinedione, 2,4-Dihydroxypyrimidine, 2,4-Pyrimidinediol

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₄H₄N₂O₂

CAS Number:

66-22-8

Molecular Weight:

112.09

Beilstein:

507828

MDL number:

MFCD00006016

UNSPSC Code:

41116107

PubChem Substance ID:

329831136

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

fluorouracil

manufacturer/tradename

EDQM

mp

>300 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1NC=CC(=O)N1

InChI

1S/C4H4N2O2/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)

InChI key

ISAKRJDGNUQOIC-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fluorouracil impurity C EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1279054

1279065

1279019

1279021

BP995

Fluorouracil, British Pharmacopoeia (BP) Reference Standard

PHR2584

5,6-Diamino-1,3-dimethyluracil, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2865

PHR2866

PHR2867

PHR2868

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

In vitro detection of the enzymatic activity of folate-dependent tRNA (Uracil-54,-C5)-methyltransferase: evolutionary implications.

Jaunius Urbonavicius et al.

Methods in enzymology, 425, 103-119 (2007-08-04)

Formation of 5-methyluridine (ribothymidine) at position 54 of the T-psi loop of tRNA is catalyzed by site-specific tRNA methyltransferases (tRNA[uracil-54,C5]-MTases). In eukaryotes and many bacteria, the methyl donor for this reaction is generally S-adenosyl-L-methionine (S-AdoMet). However, in other bacteria, like

Uracil in DNA--general mutagen, but normal intermediate in acquired immunity.

Bodil Kavli et al.

DNA repair, 6(4), 505-516 (2006-11-23)

Deamination of cytosine in DNA results in mutagenic U:G mispairs, whereas incorporation of dUMP leads to U:A pairs that may be genotoxic directly or indirectly. In both cases, uracil is mainly removed by a uracil-DNA glycosylase (UDG) that initiates the

ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

Pietro Andreone et al.

Gastroenterology, 147(2), 359-365 (2014-05-14)

The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside polymerase inhibitor), and ribavirin has shown efficacy in patients with hepatitis C virus (HCV) genotype 1b infection-the most prevalent subgenotype worldwide. We evaluated whether

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Jordan J Feld et al.

The New England journal of medicine, 370(17), 1594-1603 (2014-04-12)

The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor ombitasvir (also known as ABT-267) plus the nonnucleoside polymerase inhibitor dasabuvir (also known as ABT-333) and ribavirin has shown efficacy against the hepatitis C virus

Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation.

Goro Sashida et al.

Nature communications, 5, 4177-4177 (2014-06-24)

Loss-of-function mutations of EZH2, a catalytic component of polycomb repressive complex 2 (PRC2), are observed in ~\n10% of patients with myelodysplastic syndrome (MDS), but are rare in acute myeloid leukaemia (AML). Recent studies have shown that EZH2 mutations are often

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service